REGEN-COV cuts viral load within 7 days in COVID-19 patients

Regeneron Pharmaceuticals (NSDQ:REGN) and Roche (OTCQX: RHHBY) are touting positive results from a Phase 2/3 study investigating the potential of REGEN-COV (casirivimab and imdevimab) antibody cocktail in hospitalized COVID-19 patients. The study met its primary endpoint of reducing viral load within one week in seronegative patients needing low-flow or no supplemental oxygen.

REGEN-COV, known as Ronapreve outside of the U.S., led to a 36% reduced risk of death by day 29 in the overall treatment population.

“These new results, combined with the nearly 10,000-patient RECOVERY trial, further validate how REGEN-COV can change the course of illness for patients even after they are hospitalized with COVID-19,” said Dr. George D. Yancopoulos, president and chief scientific officer at Regeneron, in a statement.

Roche has partnered with Regeneron (NSDQ: REGN) to help manufacture and distribute REGN-COV2, which Regeneron first developed.

Roche’s chief medi…

Read more
  • 0

Regeneron touts 70% death risk reduction in COVID-19 antibody drug

Regeneron Pharmaceuticals (NSDQ:REGN) announced today that its COVID-19 antibody drug reduced hospitalization and death risk by 70% in clinical trials.

The definitive Phase 3 outcomes trial in high-risk, non-hospitalized COVID-19 patients met its primary endpoint in displaying that the REGEN-COV (casirivimab with imdevimab) significantly reduced the risk of hospitalization or death by 70% (1,200 mg intravenous [IV]) and 71% (2,400 mg IV) compared by placebo, according to a news release.

REGEN-COV also met all secondary endpoints, which included a reduction in symptom duration. Additionally, a companion trial showed that the lowest dose (300 mg IV/600 mg subcutaneous) had significant viral load reductions over the first seven days, even reaching a level comparable to the highest performing doses (2,400 mg and 1,200 mg IV doses).

“This is a landmark moment in the fight against COVID-19 as this large well-controlled trial provides conclusive results d…

Read more
  • 0

FDA authorizes Eli Lilly’s monoclonal antibody treatment for COVID-19

The FDA announced that it issued emergency use authorization (EUA) for monoclonal antibodies developed by Eli Lilly (NYSE:LLY) for treating COVID-19.

Eli Lilly’s bamlanivimab and etesevimab received authorization to be administered together for treating mild to moderate COVID-19 in adults and pediatric patients over 12 years old and weighing at least 40 kilograms (about 88 pounds), according to a news release. Bamlanivimab had already received an EUA in November 2020 for treating mild-to-moderate COVID-19 cases.

Authorization for the antibody treatments is for those who test positive for SARS-CoV-2 and are at high risk for progressing to severe COVID-19. The authorized use includes treating those who are 65 years of age or older who have certain chronic medical conditions. Authorization does not include patients who are hospitalized due to COVID-19 or require oxygen therapy due to COVID-19, as the antibodies may be associated with worse clinical outcomes …

Read more
  • 0